Tempus AI, Inc. (NASDAQ:TEM) CEO Eric P. Lefkofsky Sells 562,345 Shares

Tempus AI, Inc. (NASDAQ:TEMGet Free Report) CEO Eric P. Lefkofsky sold 562,345 shares of the firm’s stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $50.93, for a total transaction of $28,640,230.85. Following the sale, the chief executive officer now directly owns 9,457,283 shares of the company’s stock, valued at approximately $481,659,423.19. The trade was a 5.61 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Tempus AI Stock Performance

Shares of TEM stock opened at $49.10 on Friday. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17. Tempus AI, Inc. has a 52 week low of $22.89 and a 52 week high of $91.45. The firm’s 50-day simple moving average is $54.02 and its two-hundred day simple moving average is $52.54.

Institutional Trading of Tempus AI

A number of hedge funds and other institutional investors have recently bought and sold shares of TEM. ARK Investment Management LLC grew its stake in Tempus AI by 132.1% in the 4th quarter. ARK Investment Management LLC now owns 5,519,644 shares of the company’s stock worth $186,343,000 after buying an additional 3,141,487 shares in the last quarter. NEA Management Company LLC increased its stake in shares of Tempus AI by 17.8% in the 3rd quarter. NEA Management Company LLC now owns 5,385,979 shares of the company’s stock worth $304,846,000 after acquiring an additional 813,169 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. increased its stake in shares of Tempus AI by 166.0% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,239,093 shares of the company’s stock worth $109,352,000 after acquiring an additional 2,021,394 shares in the last quarter. Nikko Asset Management Americas Inc. grew its position in Tempus AI by 166.0% during the 4th quarter. Nikko Asset Management Americas Inc. now owns 3,239,093 shares of the company’s stock valued at $109,352,000 after purchasing an additional 2,021,394 shares during the last quarter. Finally, Franklin Resources Inc. grew its position in Tempus AI by 240.5% during the 4th quarter. Franklin Resources Inc. now owns 2,762,173 shares of the company’s stock valued at $93,251,000 after purchasing an additional 1,950,862 shares during the last quarter. Institutional investors own 24.22% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. JPMorgan Chase & Co. lowered shares of Tempus AI from an “overweight” rating to a “neutral” rating and raised their price target for the company from $50.00 to $55.00 in a report on Tuesday, February 25th. Guggenheim reaffirmed a “buy” rating on shares of Tempus AI in a research report on Tuesday, February 25th. Wolfe Research cut shares of Tempus AI from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 26th. Loop Capital lowered their price target on shares of Tempus AI from $57.00 to $52.00 and set a “buy” rating on the stock in a research note on Tuesday, January 14th. Finally, Stifel Nicolaus lowered shares of Tempus AI from a “buy” rating to a “hold” rating and boosted their price objective for the stock from $45.00 to $65.00 in a research note on Monday, November 11th. Six investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $61.18.

Read Our Latest Stock Analysis on Tempus AI

About Tempus AI

(Get Free Report)

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.

Further Reading

Insider Buying and Selling by Quarter for Tempus AI (NASDAQ:TEM)

Receive News & Ratings for Tempus AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempus AI and related companies with MarketBeat.com's FREE daily email newsletter.